Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical Group (STU:S2P) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Simcere Pharmaceutical Group Operating Margin % Related Terms
Simcere Pharmaceutical Group Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Operating Margin % Chart
STU:S2P vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Operating Margin % falls into.
Simcere Pharmaceutical Group Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (STU:S2P) has a Operating Margin % of 16.54% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Simcere Pharmaceutical Group and its competitors. This is near median its historical median of 16.47. Over the past decade, Simcere Pharmaceutical Group's Operating Margin % has ranged from 3.92 to 22.43. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #210 out of 959 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Simcere Pharmaceutical Group's Operating Margin % too high?
Simcere Pharmaceutical Group's current Operating Margin % of 16.54% is near median its 10-year median of 16.47. Over the past 10 years, this metric has ranged from a low of 3.92 to a high of 22.43. The Drug Manufacturers industry median Operating Margin % is 7.57. Simcere Pharmaceutical Group's value of 16.54% is 118.5% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #210 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #210 out of 959 companies for Operating Margin %. This places Simcere Pharmaceutical Group in the top 22% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.57. Simcere Pharmaceutical Group's value of 16.54% is 118.5% above this benchmark. Historically, Simcere Pharmaceutical Group's own Operating Margin % has ranged from 3.92 to 22.43 over the past decade. While the company's 10-year median is 16.47 vs. the industry median of 7.57, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Operating Margin % of 16.54% is 118.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Operating Margin % is 16.54%, which is near median its own 10-year median of 16.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current Operating Margin % of 16.54%. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current Operating Margin % is 16.54%, which is near median its 10-year median of 16.47 and 118.5% above the Drug Manufacturers industry median of 7.57. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current Operating Margin % is 16.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.
Key valuation signals for STU:S2P:
Operating Margin %: 16.54% (near median its 10-year median of 16.47)
GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
Industry Position: 118.5% above the Drug Manufacturers median (#210 of 959)
No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for STU:S2P
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S2P has been successfully added to your 
